A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 257
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : EASL
Long Form : European Association for the Study of the Liver
No. Year Title Co-occurring Abbreviation
2022 Comparison of MRI-based response criteria and radiomics for the prediction of early response to transarterial radioembolization in patients with hepatocellular carcinoma. HCC, mRECIST, MRI, ROC, TARE
2022 Early Treatment Consideration in Patients with Hepatitis B 'e' Antigen-Positive Chronic Infection: Is It Time for a Paradigm Shift? CHB, HBeAg, HCC
2022 New Liver MR Imaging Hallmarks for Small Hepatocellular Carcinoma Screening and Diagnosing in High-Risk Patients. ECA, HBSC, HCC
2022 Reliability of extracellular contrast versus gadoxetic acid in assessing small liver lesions using liver imaging reporting and data system v.2018 and European association for the study of the liver criteria. ECAs, GA, LI-RADS
2022 Setting Up a Local Registry to Improve the Care of Patients With Primary Biliary Cholangitis. BSG, PBC
2022 Simplifying Treatment Criteria in Chronic Hepatitis B: Reducing Barriers to Elimination. AASLD, AATA, APASL, CHB, HBV
2021 A consensus integrated care pathway for patients with primary biliary cholangitis: a guideline-based approach to clinical care of patients. PBC
2021 Advances in treatment and prevention of hepatitis B. AASLD, APASL, CHB
2021 Anti-HEV IgG Avidity Testing: Utility for Diagnosing Acute and Resolved Genotype 3 Infections. GT3
10  2021 Brazilian Society of Hepatology and Brazilian College of Radiology practice guidance for the use of elastography in liver diseases. ALEH, SBH
11  2021 Comparison of LI-RADS with other non-invasive liver MRI criteria and radiological opinion for diagnosing hepatocellular carcinoma in cirrhotic livers using gadoxetic acid with histopathological explant correlation. APASL, HCC, JSH, LI-RADS, MRI, OPTN, PPV
12  2021 Comparison of the current guidelines for diagnosing hepatocellular carcinoma using gadoxetic acid-enhanced magnetic resonance imaging. APASL, CI, HCCs, KLCSG-NCC, LI-RADS, MRI
13  2021 COVID-19 in Chronic Liver Disease and Liver Transplantation: A Clinical Review. AASLD, APASL, COVID-19
14  2021 Demographics, Biochemical Characteristics, and Phases of Chronic Hepatitis B Virus Infection: Retrospective Analysis From a Secondary Care Setup. ALT, DAAs, DCLD, HBV, phases II and IV
15  2021 Estimating the attributable fraction of cirrhosis and hepatocellular carcinoma due to hepatitis B and C. ECDC, HCC
16  2021 Evaluation of Five International HBV Treatment Guidelines: Recommendation for Resource-Limited Developing Countries Based on the National Study in Nepal. AASLD, APASL, AST, HBV, NICE, WHO
17  2021 Evaluation of the Relationship between Insulin Resistance and HBV DNA Level in Patients with HBeAg-negative Chronic HBV Infection (Natural Course Phase 3). BMI, CHB, GGT, HBV, HDL, HOMA-IR, TG, USG, VLDL
18  2021 Evidence-based clinical practice guidelines for liver cirrhosis 2020. AASLD, ASH/NASH, BQs, CQs, FRQs, JSGE, JSH
19  2021 Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. AASLD, ASH/NASH, BQs, CQs, FRQs, JSGE, JSH
20  2021 Hepatitis E: Genotypes, strategies to prevent and manage, and the existing knowledge gaps. HEV, WHO
21  2021 Lipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial. cTACE, mOS, mRECIST
22  2021 Non-invasive imaging criteria for the diagnosis of hepatocellular carcinoma in non-cirrhotic patients with chronic hepatitis B. HCC, LI-RADS, TIV
23  2021 Predictors and outcome of emergent Liver transplantation for patients with acute-on-chronic liver failure. ACLF, CLIF-SOFA, LT, MELD
24  2021 Prevalence of drug-drug interactions with pangenotypic direct-acting antivirals for hepatitis C and real-world care management in the United States: a retrospective observational study. AASLD, DAA, DDIs, GLE-PIB, HCV, SOF-VEL
25  2021 Scoping review of clinical practice guidelines on the management of benign liver tumours. ACG, AGREE II, BLT, FNH, HCA, PRISMA
26  2021 Therapeutic plasma exchange in children with acute liver failure (ALF): is it time for incorporation into the ALF armamentarium? ALF, PALF
27  2021 Widespread gaps in the quality of care for primary biliary cholangitis in UK. PBC, UDCA
28  2021 [The European Association for the Study of Liver (EASL) nutrition guidelines.] ---
29  2020 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. AASLD, BCLC, CNLC, HBV, HCC, ICIs, TACE
30  2020 Alcohol-related liver diseases (ALD). ALD, AUD
31  2020 Alcohol-related liver diseases. ---
32  2020 Chronic hepatitis B in children, report of a single-centre longitudinal study on 152 children. HBV
33  2020 Comparative study on guidelines in determining HBV phases in Iranian patients. AASLD, ACG, APASL, HBV
34  2020 Comparison of guidelines for diagnosis of hepatocellular carcinoma using gadoxetic acid-enhanced MRI in transplantation candidates. AASLD, APASL, KLCA-NCC, MC
35  2020 Comparison of the diagnostic performance of imaging criteria for HCCs ≤ 3.0cm on gadoxetate disodium-enhanced MRI. APASL, HCC, KLCA-NCC, LI-RADS, MRI
36  2020 EASL clinical practice guidelines for the management of occupational liver diseases. CPG, OLD
37  2020 Eligibility for hepatitis B antiviral therapy among adults in the general population in Zambia. aOR, ART, AUROC, AVT, CI, HBsAg, HBV, WHO
38  2020 Empirical 188Re-HDD/lipiodol intra-arterial therapy based on tumor volume, in patients with solitary inoperable hepatocellular carcinoma. AFP, CECT, HCC, RECIST, SPECT-CT
39  2020 Hepatitis B: Who to treat? A critical review of international guidelines. AASLD, APASL, HCC, WHO
40  2020 How Much Liver Tissue Is Required for Sufficient Histological Staging in Patients with Primary Biliary Cholangitis? ARFI, MLFS, PBC
41  2020 Infection deteriorating hepatitis B virus related acute-on-chronic liver failure: a retrospective cohort study. ACLF, HBV-ACLF
42  2020 Prediction of overall survival in patients with hepatocellular carcinoma treated with Y-90 radioembolization by imaging response criteria. BCLC, HCC, HR, mRECIST, qEASL, RECIST, TARE, vRECIST
43  2020 Reasons to consider early treatment in chronic hepatitis B patients. CHB, HBeAg, HCC
44  2020 Role of Contrast-Enhanced Ultrasound as a Second-Line Diagnostic Modality in Noninvasive Diagnostic Algorithms for Hepatocellular Carcinoma. APHE, CEUS, HCC, KLCA-NCC
45  2020 Safety and Efficacy of Segmental Yttrium-90 Radioembolization for Hepatocellular Carcinoma after Transjugular Intrahepatic Portosystemic Shunt Creation. HCC, OLT, OS, TIPS, TTP, WHO
46  2020 Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications. AER, AST, CKD, CVD, FIB-4, FLI, NAFLD, NFS
47  2020 Screening strategies for nonalcoholic fatty liver disease in type 2 diabetes: Insights from NHANES 2005-2016. NAFLD, NHANES, T2DM
48  2020 Spontaneous Bacterial Peritonitis: We Are Still Behind. AASLD, SBP
49  2020 [Several issues worthy of reference and discussion of 2019 edition of the European Association for the Study of the Liver guideline for drug-induced liver injury]. DILI
50  2019 Alcohol-Related Liver Disease: Areas of Consensus, Unmet Needs and Opportunities for Further Study. AASLD
51  2019 Alcohol-related liver disease: Areas of consensus, unmet needs and opportunities for further study. AASLD
52  2019 Alpha-fetoprotein assessment for hepatocellular carcinoma after transarterial chemoembolization. HCC, HR, OS, TACE
53  2019 Clinical practice guidelines in Wilson disease. AASLD, ALF, ESPGHAN, WD
54  2019 Clinical presentations of Hepatitis E: A clinical review with representative case histories. BTS, HEV
55  2019 Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update. AASLD, APASL, HCC, KLCA-NCC, LI-RADS, MRI
56  2019 Complications constitute a major risk factor for mortality in hepatitis B virus-related acute-on-chronic liver failure patients: a multi-national study from the Asia-Pacific region. AARC, AARC-ACLFs, CLIF-C OFs, CLIF-C-ACLFs, COSSH-ACLFs, HBV-ACLF, MELDs, TPPMs
57  2019 Emerging Role of Hepatobiliary Magnetic Resonance Contrast Media and Contrast-Enhanced Ultrasound for Noninvasive Diagnosis of Hepatocellular Carcinoma: Emphasis on Recent Updates in Major Guidelines. CEUS, CT, HCC, KLCA-NCC, MRI
58  2019 First-Line Selective Internal Radiation Therapy in Patients with Uveal Melanoma Metastatic to the Liver. HR, SIRT
59  2019 Incidence and Mortality of Acute-on-Chronic Liver Failure Using Two Definitions in Patients with Compensated Cirrhosis. ACLF, APASL, CI
60  2019 Joint Consensus Statement of the Indian National Association for Study of the Liverand Indian Radiological and Imaging Associationfor the Diagnosis and Imaging of Hepatocellular CarcinomaIncorporating Liver Imaging Reporting and Data System. AASLD, HCC
61  2019 Local Tumor Control and Patient Outcome Using Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: iRECIST as a Potential Substitute for Traditional Criteria. HCC, iRECIST, mRECIST, RECIST 1.1, SBRT, WHO
62  2019 Man or machine? Prospective comparison of the version 2018 EASL, LI-RADS criteria and a radiomics model to diagnose hepatocellular carcinoma. AUCs, HBV, HCC, LI-RADS, MR
63  2019 Radiomics machine-learning signature for diagnosis of hepatocellular carcinoma in cirrhotic patients with indeterminate liver nodules. AUC, HCC, pts
64  2019 Retrospective comparison of EASL 2018 and LI-RADS 2018 for the noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging. HCC, LI-RADS, MRI
65  2019 Screening, diagnosis and risks associated with Hepatitis E virus infection. HEV
66  2019 The risk of hepatocellular carcinoma among chronic hepatitis B virus-infected patients outside current treatment criteria. AASLD, APASL, HCC
67  2019 The WHO guidelines for chronic hepatitis B fail to detect half of the patients in need of treatment in Ethiopia. CHB, WHO
68  2019 Wilson Disease Presenting With Acute on Chronic Liver Failure: A Single-Center Experience of Outcome and Predictors of Mortality in 68 Patients. ACLF, MELD, WD
69  2019 [Recent advances in understanding and diagnosing hepatitis B virus infection]. HBcrAg, HBsAg, HBV
70  2018 A multicenter pilot survey to clarify the clinical features of patients with acute-on-chronic liver failure in Japan. ACLF, APASL, Clif, CMA
71  2018 Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients With Chronic Hepatitis C Infection. CI, EOT, HCV, ITT, SOF/DCV, SVR12
72  2018 European Association for the Study of the Liver and French hepatitis C recent guidelines: The paradigm shift. AFEF, HCV
73  2018 Expert opinion on the management of hepatitis C infection in Kuwait. AASLD, HCV, KHC
74  2018 Late Presentation for Care Among Patients With Chronic Hepatitis C: Prevalence and Risk Factors. LP
75  2018 Living Donor Liver Transplantation for Acute-on-Chronic Liver Failure. ACLF, LDLT, LT
76  2018 Management of acute HCV infection in the era of direct-acting antiviral therapy. AASLD, DAAs
77  2018 Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend. CHB, HBeAg, HBV
78  2018 Management of Chronic Hepatitis B: Knowledge and Practices of Physicians in Pakistan. AASLD, APASL, CHB, HBV
79  2018 Radiation Segmentectomy: Potential Curative Therapy for Early Hepatocellular Carcinoma. HCC, RS, WHO
80  2018 Radiologic criteria of response to systemic treatments for hepatocellular carcinoma. mRECIST, RECICL, RECIST
81  2018 Rates of sustained virological response 12weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy? DAA, HCV, SVR12
82  2018 Treatment of hepatitis C: Results in real life. DAAs, HCV
83  2018 Well-controlled autoimmune hepatitis treatment withdrawal may be safely accomplished without liver-biopsy guidance. AASLD, AST
84  2018 [Investigation of antinuclear antibodies in chronic hepatitis B patients]. AMA, ANA, ASMA, ENA, IIF, LKM
85  2017 Acute-on-chronic liver failure in a multi-ethnic Asian city: A comparison of patients identified by Asia-Pacific Association for the Study of the Liver and European Association for the Study of the Liver definitions. ACLF, APASL
86  2017 Current treatment guidelines of chronic hepatitis B: The role of nucleos(t)ide analogues and peginterferon. AASLD, APASL
87  2017 Diagnostic Imaging of Hepatocellular Carcinoma - A Pictorial Essay. EORTC, HCC
88  2017 Early experiences from one of the first treatment programs for chronic hepatitis B in sub-Saharan Africa. CHB, HBeAg, TDF
89  2017 EASL International Liver Congress 2017. ---
90  2017 EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral? NAFLD, NASH, NFS, TE
91  2017 European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes. EASD, EASO
92  2017 Extracellular contrast agent-enhanced MRI: 15-min delayed phase may improve the diagnostic performance for hepatocellular carcinoma in patients with chronic liver disease. ECA, HCC, LI-RADS, MRI
93  2017 Functional hepatic imaging as a biomarker of primary and secondary tumor response to loco-regional therapies. ADC, CT, DCE-MRI, DWI, HAI, LRT, mRECIST, MRI, PCT, RECIST, RFA, TACE
94  2017 Hepatitis C in injection drug users: It is time to treat. DAAs, HCV, IDUs, SVR
95  2017 Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial. HCV, SVR12
96  2017 Radioembolization for hepatocellular carcinoma: Statistical confirmation of improved survival in responders by landmark analyses. CI, HCC, HR, PD, RECIST 1.1, SD
97  2017 Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation. CR, HCC, LT, mRECIST, PLR, PR, TACE, UCSF
98  2017 Response Tailored Protocol Versus the Fixed 12Weeks Course of Dual Sofosbuvir/Daclatasvir Treatment in Egyptian Patients With Chronic Hepatitis C Genotype-4 Infection: A Randomized, Open-label, Non-inferiority Trial. CI, ITT, PP, SOF/DCV
99  2017 Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. CCA, ERCP, ESGE, MRC
100  2017 Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. ESGE, GRADE